Reduction in heavy drinking as a treatment outcome in alcohol dependence.
paper
Cited
Public
Unavailable
- Authors
- Gastfriend, David R; Garbutt, James C; Pettinati, Helen M; Forman, Robert F
- Year
- 2007
- Journal
- Journal of substance abuse treatment
- PMID
- 17588491
- DOI
- 10.1016/j.jsat.2006.09.008
In the field of clinical alcohol disorders treatment in North America, abstinence continues to be largely viewed as the optimal treatment goal; however, there is a growing awareness of limitations when abstinence is considered the only successful outcome. Although this issue has been discussed in research settings, new studies on the public health significance of heavy drinking (defined as five or more standard drinks per drinking day in men, and four or more standard drinks per drinking day in women) in the past 10 years suggest that clinical providers should consider the value of alternative outcomes besides abstinence. A focus on abstinence as the primary outcome fails to capture the impact of treatment on reduction in the pattern and in the frequency of alcohol consumption. In addition, evaluating reduction in drinking as "positive" has value for patients as an indicator of clinical progress. Measurement of continuous variables, such as the quantity and the frequency of alcohol consumption, has provided a clearer understanding of the scope of alcohol-related morbidity and mortality at the societal level, and of the relationship between individual patient characteristics and the naturalistic course of alcohol use, abuse, and dependence. A review of these characteristics suggests that there are clinical benefits associated with reducing heavy drinking in alcohol-dependent patients. Given the significant public health consequences associated with heavy drinking and the benefits associated with its reduction, it is proposed that researchers, public health professionals, and clinicians consider using reduction in heavy drinking as a meaningful clinical indicator of treatment response, and that outcomes be individualized to patients' goals and readiness to change.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| A 22-Year Follow-Up (Range 16 to 23) of Original Subjects with Baseline Alcohol Use Disorders from the Collaborative Study on Genetics of Alcoholism. | 2018 | 29975427 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Hypertension and its associated risk factors in tuberculosis patients: A hospital based cross-sectional study. | Tan Y et al. | β | 2026 | β |
| Alcohol use disorders and liver fibrosis: an update. | Caputo F et al. | β | 2024 | β |
| 'Butββ¦βWould I Be Able to Toast With Friends?' When Service Users Ask for New Care Pathways. | Rocelli M et al. | β | 2024 | β |
| Exploring Attentional Bias toward Alcohol Content: Insights from Eye-Movement Activity. | GhiΕ£Δ A et al. | β | 2024 | β |
| Gut Hormones: Possible Mediators of Addictive Disorders? | Nestor LJ et al. | β | 2024 | β |
| Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial. | Vanderijst L et al. | β | 2024 | β |
| Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Protocol for a Double-Blind, Randomized, Placebo-Controlled, 7-month Parallel-Group Phase II Superiority Trial | Vanderijst L et al. | β | 2024 | β |
| Regional cortical brain volumes at treatment entry relates to post treatment WHO risk drinking levels in those with alcohol use disorder. | Durazzo TC et al. | β | 2024 | β |
| Alcohol use and the longitudinal HIV care continuum for people with HIV who enrolled in care between 2011 and 2019. | Lesko CR et al. | β | 2023 | β |
| Non-abstinent recovery in alcohol use disorder is associated with greater regional cortical volumes than heavy drinking. | May AC et al. | β | 2023 | β |
| Efficacy of repetitive transcranial magnetic stimulation (rTMS) for reducing consumption in patients with alcohol use disorders (ALCOSTIM): study protocol for a randomized controlled trial. | Petit B et al. | β | 2022 | β |
| Predictors of abstinence, no heavy drinking days, and a 2-level reduction in World Health Organization drinking levels during treatment for alcohol use disorder in the COMBINE study. | Wallach JD et al. | β | 2022 | β |
| Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial). | Jensen ME et al. | β | 2022 | β |
| Computer-delivered brief alcohol intervention for patients with liver disease: a randomized controlled trial. | Cucciare MA et al. | β | 2021 | β |
| Decreased Alcohol Consumption in an Implementation Study of Computerized Brief Intervention among HIV Patients in Clinical Care. | McCaul ME et al. | β | 2021 | β |
| Disrupted H<sub>2</sub>S Signaling by Cigarette Smoking and Alcohol Drinking: Evidence from Cellular, Animal, and Clinical Studies. | Read E et al. | β | 2021 | β |
| Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a dose-response, randomized, controlled trial. | Garbutt JC et al. | β | 2021 | β |
| Missed opportunities by health care providers to reduce racial/ethnic disparities in the use of alcohol treatment services. | Pinedo M | β | 2021 | β |
| Safety and Persistence of Nalmefene Treatment for Alcohol Dependence. Results from Two Post-authorisation Safety Studies. | Chick J et al. | β | 2021 | β |
| Understanding low treatment seeking rates for alcohol use disorder: A narrative review of the literature and opportunities for improvement. | Venegas A et al. | β | 2021 | β |
| Liver transplantation in patients with alcohol-related liver disease: current status and future directions. | Mathurin P et al. | β | 2020 | β |
| Open-label Study with Nalmefene as Needed Use in Alcohol-Dependent Patients with Evidence of Elevated Liver Stiffness and/or Hepatic Steatosis. | Mueller S et al. | β | 2020 | β |
| The Many Levels of Relapse to Drinking: Commentary on Meyerhoff and Durazzo (ACER 2020). | Sullivan EV | β | 2020 | β |
| Individual differences in the effect of menstrual cycle on basal ganglia inhibitory control. | Hidalgo-Lopez E et al. | β | 2019 | β |
| Nalmefene in alcohol-dependent patients with a high drinking risk: Randomized controlled trial. | Miyata H et al. | β | 2019 | β |
| Strategies to increase implementation of pharmacotherapy for alcohol use disorders: a structured review of care delivery and implementation interventions. | Williams EC et al. | β | 2019 | β |
| A 22-Year Follow-Up (Range 16 to 23) of Original Subjects with Baseline Alcohol Use Disorders from the Collaborative Study on Genetics of Alcoholism. | Schuckit MA et al. | β | 2018 | β |
| Alcohol-Related Nurse Care Management in Primary Care: A Randomized Clinical Trial. | Bradley KA et al. | β | 2018 | β |
| Decreased olfactory discrimination is associated with impulsivity in healthy volunteers. | Herman AM et al. | β | 2018 | β |
| Deep Brain Stimulation of the Internal Globus Pallidus Improves Response Initiation and Proactive Inhibition in Patients With Parkinson's Disease. | Pan Y et al. | β | 2018 | β |
| Reply to Braillon et al.:Β Nalmefene Phase IV Study: A Seeding Flying in the Face of Evidence? | Barrio P et al. | β | 2018 | β |
| The effects of theta burst stimulation (TBS) targeting the prefrontal cortex on executive functioning: A systematic review and meta-analysis. | Lowe CJ et al. | β | 2018 | β |
| Treatment for Alcohol Use Disorder: Progress in Predicting Treatment Outcome and Validating Nonabstinent End Points. | Creswell KG et al. | β | 2018 | β |
| Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results. | Barrio P et al. | β | 2018 | β |
| Clinical Validation of Reduced Alcohol Consumption After Treatment for Alcohol Dependence Using the World Health Organization Risk Drinking Levels. | Witkiewitz K et al. | β | 2017 | β |
| Drinking Status Between Ages 50 and 55 for Men From the San Diego Prospective Study Who Developed DSM-IV Alcohol Abuse or Dependence in Prior Follow-Ups. | GonΓ§alves PD et al. | β | 2017 | β |
| Nalmefene in Alcohol Use Disorder Subjects with Psychiatric Comorbidity: A Naturalistic Study. | Di Nicola M et al. | β | 2017 | β |
| Patient-centered primary care for adults at high risk for AUDs: the Choosing Healthier Drinking Options In primary CarE (CHOICE) trial. | Bradley KA et al. | β | 2017 | β |
| Patients' Knowledge and Attitudes Towards Regular Alcohol Urine Screening: A Survey Study. | Barrio P et al. | β | 2017 | β |
| Self-management and Shared Decision-Making in Alcohol Dependence via a Mobile App: a Pilot Study. | Barrio P et al. | β | 2017 | β |
| Variation in receipt of pharmacotherapy for alcohol use disorders across racial/ethnic groups: A national study in the U.S. Veterans Health Administration. | Williams EC et al. | β | 2017 | β |
| A Brief Up-Date of the Use of Sodium Oxybate for the Treatment of Alcohol Use Disorder. | Caputo F et al. | β | 2016 | β |
| Efficacy of transcranial direct current stimulation (tDCS) in reducing consumption in patients with alcohol use disorders: study protocol for a randomized controlled trial. | Trojak B et al. | β | 2016 | β |
| Patient-centered care interventions for the management of alcohol use disorders: a systematic review of randomized controlled trials. | Barrio P et al. | β | 2016 | β |
| Pharmacotherapy for Alcohol Dependence: The 2015 Recommendations of the French Alcohol Society, Issued in Partnership with the European Federation of Addiction Societies. | Rolland B et al. | β | 2016 | β |
| The Cost-Effectiveness of the Integration of Nalmefene within the UK Healthcare System Treatment Pathway for Alcohol Dependence. | LaramΓ©e P et al. | β | 2016 | β |
| Harm Reduction as "Continuum Care" in Alcohol Abuse Disorder. | Maremmani I et al. | β | 2015 | β |
| Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme. | van den Brink W et al. | β | 2015 | β |
| The New French Guidelines on Alcohol Misuse: An Initiative for Strengthening Cross-European Interplay. | Rolland B et al. | β | 2015 | β |
| Transdermal alcohol concentration data collected during a contingency management program to reduce at-risk drinking. | Dougherty DM et al. | β | 2015 | β |
| A 5-year follow-up of depressed and bipolar patients with alcohol use disorder in an Irish population. | Farren CK et al. | β | 2014 | β |
| Alcoholism risk reduction in France: a modernised approach related to alcohol misuse disorders. | Brousse G et al. | β | 2014 | β |
| Brief interventions for hazardous and harmful alcohol consumption in accident and emergency departments. | Wojnar M et al. | β | 2014 | β |
| Can alcohol dependent patients adhere to an 'as-needed' medication regimen? | Sinclair J et al. | β | 2014 | β |
| Efficacy of disulfiram for the treatment of alcohol dependence assessed with a multicenter randomized controlled trial. | Yoshimura A et al. | β | 2014 | β |
| Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study. | van den Brink W et al. | β | 2014 | β |
| Low-dose topiramate in alcohol dependence: a single-blind, placebo-controlled study. | Martinotti G et al. | β | 2014 | β |
| Nalmefene: a new approach to the treatment of alcohol dependence. | Paille F et al. | β | 2014 | β |
| Randomized controlled trial of MICBT for co-existing alcohol misuse and depression: outcomes to 36-months. | Baker AL et al. | β | 2014 | β |
| A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. | Gual A et al. | β | 2013 | β |
| Emerging pharmacotherapies for alcohol dependence: a systematic review focusing on reduction in consumption. | Aubin HJ et al. | β | 2013 | β |
| Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. | Mann K et al. | β | 2013 | β |
| Nalmefene: a review of its use in the treatment of alcohol dependence. | Keating GM | β | 2013 | β |
| Predicting persistency of DSM-5 alcohol use disorder and examining drinking patterns of recently remitted individuals: a prospective general population study. | Tuithof M et al. | β | 2013 | β |
| Pretreatment alcohol drinking goals are associated with treatment outcomes. | Dunn KE et al. | β | 2013 | β |
| Reduced-risk drinking as a viable treatment goal in problematic alcohol use and alcohol dependence. | van Amsterdam J et al. | β | 2013 | β |
| The effects of drinking goal on treatment outcome for alcoholism. | Bujarski S et al. | β | 2013 | β |
| The high harm score of alcohol. Time for drug policy to be revisited? | van Amsterdam J et al. | β | 2013 | β |
| Factors predicting change in frequency of heavy drinking days among alcohol-dependent participants in the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). | Sarsour K et al. | β | 2012 | β |
| Predictors of moderated drinking in a primarily alcohol-dependent sample of men who have sex with men. | Kuerbis A et al. | β | 2012 | β |
| The predictive validity of the Drinking-Related Cognitions Scale in alcohol-dependent patients under abstinence-oriented treatment. | Sawayama T et al. | β | 2012 | β |
| Treatment seeking and subsequent 1-year drinking outcomes among treatment clients in Sweden and the U.S.A.: a cross-cultural comparison. | Witbrodt J et al. | β | 2012 | β |
| Assessing drug use during follow-up: direct comparison of candidate outcome definitions in pooled analyses of addiction treatment studies. | Korte JE et al. | β | 2011 | β |
| Clinical correlates of desire for treatment for current alcohol dependence among patients with a primary psychiatric disorder. | Ray LA et al. | β | 2011 | β |
| Patient relapse in the context of drug abuse treatment. | Condon TP et al. | β | 2011 | β |
| Acetyl-L-carnitine for alcohol craving and relapse prevention in anhedonic alcoholics: a randomized, double-blind, placebo-controlled pilot trial. | Martinotti G et al. | β | 2010 | β |
| Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial. | Martinotti G et al. | β | 2010 | β |
| When should clinicians switch treatments? An application of signal detection theory to two treatments for women with alcohol use disorders. | Hildebrandt T et al. | β | 2010 | β |
| Characterization of a functional polymorphism in the 3' UTR of SLC6A4 and its association with drinking intensity. | Seneviratne C et al. | β | 2009 | β |
| Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients. | Pettinati HM et al. | β | 2009 | β |
| Suppression of heavy drinking and alcohol seeking by a selective ALDH-2 inhibitor. | Arolfo MP et al. | β | 2009 | β |
| The role of brief motivational intervention on self-efficacy and abstinence in a cohort of patients with alcohol dependence. | Romo L et al. | β | 2009 | β |
| Reducing heavy drinking: a public health strategy and a treatment goal? | McLellan AT | β | 2007 | β |